Ascendis Pharma A/S (ASND)
| Market Cap | 7.72B |
| Revenue (ttm) | 10.63M |
| Net Income (ttm) | -428.99M |
| Shares Out | 52.72M |
| EPS (ttm) | -3.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 8 |
| Last Price | $141.26 |
| Previous Close | $146.91 |
| Change ($) | -5.65 |
| Change (%) | -3.85% |
| Day's Open | 145.00 |
| Day's Range | 140.31 - 148.00 |
| Day's Volume | 235,997 |
| 52-Week Range | 92.00 - 183.98 |
COPENHAGEN, Denmark, March 04, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product ca...
COPENHAGEN, Denmark, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medic...
COPENHAGEN, Denmark, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product can...
If you screen the market for stocks that have a current ratio higher than 2 and more working capital than long-term debt, as Benjamin Graham, the pioneer of value investing, recommended, the c...
MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the planned addition of Albert Cha, M.D., Ph.D. as Managing Partner on the Life Sciences team. He has over 20 years o...
COPENHAGEN, Denmark, Jan. 10, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product can...
– Advances Vision 3x3 to extend global clinical and commercial reach –
COPENHAGEN, Denmark, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product can...
- TransCon TLR7/8 Agonist is designed for intratumoral, sustained release of resiquimod with minimal systemic exposure, while inducing a potent anti-tumor response -
Investors need to pay close attention to Ascendis Pharma (ASND) stock based on the movements in the options market lately.
– Chair and board member Michael Wolf Jensen will not stand for re-election at 2021 Annual General Meeting –
COPENHAGEN, Denmark, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product can...
Ascendis has a PDUFA date of June 25, 2021 for its lead indication. However, what makes this pre-market stage company so valuable is its TransCon platform.
Ascendis Pharma's (ASND) CEO Jan Mikkelsen on Q3 2020 Results - Earnings Call Transcript
– Event will provide an overview of how A s cendis is applying its TransCon ™ technology platform and its unique algorithm for product innovation to the therapeutic area of o ncology –
Shares of Ascendis Pharma (NASDAQ:ASND) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 365.52% over the past year to ($...
– European Medicines Agency (EMA) validated the Marketing Authorisation Application (MAA) f or TransCon TM hGH (lonapegsomatropin) in pediatric growth hormone deficiency (GHD) –
Ascendis (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
COPENHAGEN, Denmark, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medi...
COPENHAGEN, Denmark, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medi...
COPENHAGEN, Denmark, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medic...
COPENHAGEN, Denmark, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medi...
Ascendis Pharma (ASND) reports encouraging preliminary data on its hypoparathyroidism candidate, TransCon PTH. A late-stage study is anticipated to begin soon.
- Six-month data from PaTH Forward open-label extension support potential use of TransCon PTH as a hormone replacement therapy for adult hypoparathyroidism –
COPENHAGEN, Denmark, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet me...
– Introduces #Together4Growth to increase awareness of children’s growth disorders, including a four-question Growth Quiz to help parents identify signs and symptoms –
COPENHAGEN, Denmark, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet m...
COPENHAGEN, Denmark, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet me...
Ascendis Pharma sees its Relative Strength Rating reach the 80-plus level. The post Stocks Showing Rising Market Leadership: Ascendis Pharma Earns 82 RS Rating appeared first on Investor's Bus...
COPENHAGEN, Denmark, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that uses its novel TransCon technologies to address unmet medical nee...
– Prescription Drug User Fee Act (PDUFA) target action date of June 25, 2021 –
COPENHAGEN, Denmark, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet me...
COPENHAGEN, Denmark, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet m...
Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q2 2020 Results - Earnings Call Transcript
Shares of Ascendis Pharma (NASDAQ:ASND) were unchanged after the company reported Q2 results.
– U.S. Biologics License Application for TransCon ™ hGH submitted to U.S. Food and Drug Administration for pediatric growth hormone deficiency –
COPENHAGEN, Denmark, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet me...
Ascendis' (ASND) TransCon CNP receives an Orphan Drug tag in Europe for the treatment of achondroplasia, the most common type of dwarfism.
COPENHAGEN, Denmark, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet med...
COPENHAGEN, Denmark, July 07, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet med...
COPENHAGEN, Denmark, July 06, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet med...
– Supports the investigation of TransCon hGH for treatment of growth hormone deficiency in the pediatric population from 6 months to less than 18 years of age –
Ascendis Pharma (ASND) submits BLA to the FDA for TransConhGH for the treatment of pediatric growth hormone deficiency.
– European marketing application on track for third quarter 2020 submission – – European marketing application on track for third quarter 2020 submission –
- In vitro data demonstrated selective binding and activation of IL-2 β/γ receptor, associated with reduced IL-2 α receptor binding -
When building your watchlist, focus on stocks with an 80 or higher RS Rating. Ascendis Pharma (ASND) is one stock that just reached the mark, now earning a score of 84. If it's not there alrea...
COPENHAGEN, Denmark, June 08, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet med...
Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q1 2020 Results - Earnings Call Transcript
COPENHAGEN, Denmark, May 11, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet med...
About ASND
Ascendis Pharma A/S, a biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone which is in Phase II clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide which is in Phase II clinical for the treatment of achondroplasia. It is also developing preclinical studies in the field of oncology... [Read more...]
| Industry Biotechnology | IPO Date Jan 28, 2015 |
| CEO Jan Moeller Mikkelsen | Employees 330 |
| Stock Exchange NASDAQ | Ticker Symbol ASND |
Financial Performance
In 2019, ASND's revenue was 13.38 million, an increase of 26.41% compared to the previous year's 10.58 million. Losses were -218.02 million, 67.6% more than in 2018.
Analyst Forecasts
According to 11 analysts, the average rating for ASND stock is "Strong Buy." The 12-month stock price forecast is 189.40, which is an increase of 34.08% from the latest price.